Raltegravir (Isentress)

The Latest

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review

Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.

By Polly Clayden for HIV i-Base

This Week in HIV Research: This Is Your Brain on Stigma

The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.

By Barbara Jungwirth and Myles Helfand

Chewable Raltegravir Tablets Can Be Crushed and Dispersed in Liquid for Young Children

Chewable raltegravir tablets can be crushed and stirred until dispersed in water, apple juice or breast milk and given to younger children according to WHO weight bands.

By Polly Clayden for HIV i-Base

Isentress HD in Clinical Trials

Analyzing the data after one year, researchers found that the new formulation of raltegravir (Isentress HD) was roughly equivalent in effectiveness and safety to the older formulation.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Isentress HD: A New Once-Daily Formulation of Raltegravir Approved in Canada

In late June 2017, Health Canada licensed the sale and use of a new formulation of the anti-HIV drug raltegravir (Isentress) as part of the treatment of HIV.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.

By Polly Clayden for HIV i-Base

Raltegravir-Based Third-Line ART in Children and Adolescents

Five case studies from Uganda showed good responses in children and adolescents receiving raltegravir-based third-line ART.

By Polly Clayden for HIV i-Base

Raltegravir in HIV-Exposed Neonates

Daily raltegravir was well tolerated and met pharmacokinetic targets in full term HIV-exposed infants at high risk of infection, in a study presented at the 8th International Workshop on HIV Paediatrics.

By Polly Clayden for HIV i-Base

Raltegravir Increases Waist Circumference Compared to Boosted PIs: Greater With Use of Later ART

A large U.S. ACTG study reported significantly different body changes with raltegravir compared to combinations using a boosted PI.

By Simon Collins for HIV i-Base